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Background: Bone mineral density (BMD) and lean mass (LM) may both decrease in breast cancer survivors,
thereby increasing risk of falls and fractures. Research is needed to determine whether lean mass (LM) and fat mass
(FM) independently relate to BMD in this patient group.
Methods: The Health, Eating, Activity, and Lifestyle Study participants included 599 women, ages 29–87 years,
diagnosed from 1995–1999 with stage 0-IIIA breast cancer, who underwent dual-energy X-ray absorptiometry scans
approximately 6-months postdiagnosis. We calculated adjusted geometric means of total body BMD within quartiles (Q)
of LM and FM. We also stratified LM-BMD associations by a fat mass index threshold that tracks with obesity (lower body
fat: ≤12.9 kg/m2; higher body fat: >12.9 kg/m2) and stratified FM-BMD associations by appendicular lean mass index level
corresponding with sarcopenia (non-sarcopenic: ≥ 5.45 kg/m2 and sarcopenic: < 5.45 kg/m2).
Results: Higher LM (Q4 vs. Q1) was associated with higher total body BMD overall (1.12 g/cm2 vs. 1.07 g/cm2, p-trend
< 0.0001), and among survivors with lower body fat (1.13 g/cm2 vs. 1.07 g/cm2, p-trend < 0.0001) and higher body fat
(1.15 g/cm2 vs. 1.08 g/cm2, p-trend = 0.004). Higher FM (Q4 vs. Q1) was associated with higher total body BMD overall
(1.12 g/cm2 vs. 1.07 g/cm2, p-trend < 0.0001) and among non-sarcopenic survivors (1.15 g/cm2 vs. 1.08 g/cm2, p < 0.0001),
but the association was not significant among sarcopenic survivors (1.09 g/cm2 vs. 1.04 g/cm2, p-trend = 0.18).
Conclusion: Among breast cancer survivors, higher LM and FM were independently related to higher total body BMD.
Future exercise interventions to prevent bone loss among survivors should consider the potential relevance of increasing
and preserving LM.
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In the United States (US), over 2.5 million women are
living with a personal history of breast cancer [1,2]. Age-
related changes in body composition include a decrease
in lean mass (LM), and loss and weakening of bone,
leading to an increased risk of hip fractures and other
fractures [3]. These changes are often accelerated by* Correspondence: Stephanie.george@nih.gov
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reproduction in any medium, provided the orcancer and its treatment, including hormone therapies
such as aromatase inhibitors [3]. Skeletal weakening is a
particular concern for breast cancer survivors [4]. Com-
pared to postmenopausal osteoporotic women without
cancer, non-pathologic hip fractures in breast cancer
survivors present at an earlier age and occur paradoxic-
ally at higher bone mineral density (BMD) [5]. Research
has shown that after a diagnosis of breast cancer, survivors
may have a 15% increased risk of falls and 55% increased
risk of hip fracture [6], compared to postmenopausal
women without cancer. The sequelae of fractures lead toLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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morbidity and mortality, increased cost of disease man-
agement, and reduced quality of life [7].
Body weight has been proposed to be one of the best
determinants of BMD [8]. Heavier women have a higher
BMD because of the mechanical stress of weight on the
skeleton [9]. However, for cancer survivors, being over-
weight or obese adversely affects quality of life, may worsen
prognosis [10], and may increase the risk of chronic dis-
eases, such as diabetes, hypertension, and coronary heart
disease [11]. Further, obesity has been associated with
greater risk of fall-related injury [12] and clinical fractures
[13]. These latter associations may be due to difficulty
maintaining postural stability [14] and/or diseases such as
diabetes [14,15] which accompany obesity and are well-
known to be associated with neuropathies and poor foot
health. Because an increase in body fat over time has been
shown to be common among women being treated for
breast cancer [16-25], and because body weight does not
necessarily track with increases in adipose tissue, [26] it is
important to also understand the relationship of fat mass
and BMD among women with breast cancer.
Among postmenopausal breast cancer survivors, tar-
geted exercise training has been related to preservation
of BMD [27,28]. Targeted exercise training can addition-
ally help to prevent weight gain and concurrent losses in
LM that result from cancer and its treatment, adding to
its attractiveness as a lifestyle intervention of choice for
survivors at risk for fractures and falls. However, the tai-
loring and testing of these targeted interventions is an area
in progress [29], and given body weight’s strong relation-
ship with BMD, it is useful to evaluate how the main com-
ponents of weight, lean mass (LM) and fat mass (FM),
relate to BMD so that interventions can be tailored as
such to improve LM while reducing obesity. We explored
this critical question in the Health, Eating, Activity, and
Lifestyle (HEAL) Study of US women with early-stage
breast cancer. We hypothesized that LM and FM would
be independently related to total body BMD.
Methods
Study setting and participants
The HEAL study is a multi-ethnic prospective cohort study
that has enrolled 1,183 women with first primary breast
cancer drawn from Surveillance, Epidemiology, and End
Results (SEER) population-based cancer registries in New
Mexico, Western Washington State, and Los Angeles
County. The study was designed to determine whether life-
style, hormones, and other exposures affect breast cancer
prognosis, and details of the study have been published, in-
cluding physical activity levels of the population [30-32].
Around 6 months postdiagnosis, a subset of participants
who were enrolled at New Mexico and Washington un-
derwent a whole-body dual-energy X-ray absorptiometry(DXA) scan. To answer the study questions for this par-
ticular analysis, our sample included the women with this
measure.
In New Mexico, we recruited 615 women aged 18 years
or older, diagnosed with in situ, localized, and regional
breast cancer between July 1996 and March 1999, and
living in Bernalillo, Santa Fe, Sandoval, Valencia, or Taos
counties. In Western Washington, we recruited 202
women between ages 40 and 64 years, diagnosed with in
situ to regional breast cancer between September 1997 and
September 1998, and living in King, Pierce, or Snohomish
counties. The age range for the Washington patients was
restricted due to other ongoing breast cancer studies. Pa-
tients were eligible if they were less than 12 months post-
diagnosis. None of the patients used aromatase inhibitors;
these drugs were not licensed for clinical practice at the
time of their treatment. The study was approved by institu-
tional review boards at all sites and informed consent was
obtained from all participants. In Western Washington, a
subset of 109 of the 202 participants were offered and par-
ticipated in DXA scans; in New Mexico, all 615 participants
were offered DXA scans and 499 participated. Of the 608
women who received DXA scans, we excluded one partici-
pant who was missing data on weight, and six participants
missing data on current use of postmenopausal hormone
therapy (estrogen or estrogen plus progestin). Our final
sample included 599 women.
Data collection
DXA. We used DXA to measure whole and regional
body composition (New Mexico site: Lunar model DPX,
Lunar Radiation Corporation, Madison, WI; Washington
site: Hologic QDR 1500, Hologic, Inc., Bedford, MA).
Data from the DXA scan were used to measure total
body LM (g), FM (g), and BMD (g/cm2). Appendicular
lean mass index (ALMI) was calculated as the sum of
lean mass (fat-free, non-bone) in the arms and legs di-
vided by height in m2 [33]. We calculated fat mass index
(FMI) as fat mass in kg / height in m2. DXA provides a
highly reproducible and accurate measure for FM and
LM and is a validated and accepted method for assessing
body composition [34,35].
Additional risk factors
Breast cancer stage at diagnosis was obtained from cancer
registry records, and detailed information on treatment
and surgical procedures was abstracted from cancer regis-
try, physician, and hospital records. Height and weight
were measured in-person. Information on age, race/ethni-
city, smoking status, tamoxifen use, and postmenopausal
hormone therapy use was determined via self-report using
a standardized protocol. We categorized participants’ race/
ethnicity as non-Hispanic white (n = 406); Hispanic (n =
94); and a combined category (n = 15) which included
Table 1 Demographic, clinical and lifestyle characteristics
of 599 women in the health, eating, activity and lifestyle
study, 6 months postdiagnosis
Mean SD N %
Age (yrs) 57.5 11.4
BMI (kg/m2) 26.1 5.3
Lean mass (kg) 39.7 5.6
Appendicular lean mass (kg) 16.6 2.6
Fat mass (kg) 26.4 10.2
Bone mineral density (g/cm2) 1.1 0.1
Obesity status by FMI levels
No (FMI < =12.9 kg/m2) 474 79
Yes (FMI > 12.9 kg/m2) 125 21
Sarcopenia status
No (ALM index > =5.45 kg/m2) 515 86
Yes (ALM index < 5.45 kg/m2) 84 14
Study site
Western Washington 103 17
New Mexico 496 83
Race/ethnicity
Non-Hispanic white 464 77
Hispanic 120 20













No chemotherapy or radiation 195 33
Radiation only 250 42
Chemotherapy only 37 6
Radiation + chemotherapy 117 20
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Menopausal status was determined via self-report and
blood hormone levels of estradiol, estrone, and follicle-
stimulating hormone.
Statistical analysis
Log total body BMD values were regressed on quartiles
(Q) of LM and FM in multivariate models, and beta scores
were exponentiated and expressed as geometric means.
We also performed the test for linear trend across categor-
ies of LM and FM, by assigning participants the median
value of their categories and entering it as a continuous
term in a regression model.
We also stratified the LM-BMD association by a FMI
threshold for body that tracks with obesity status (lower
body fat: <=12.9 kg/m2; higher body fat: >12.9 kg/m2)
[36]. Similarly, we stratified the FM-BMD association by
sarcopenia status using the ALMI cut point (non-sarco-
penic: ≥ 5.45 kg/m2; sarcopenic: < 5.45 kg/m2) [37,38].
For model building, we identified risk factors that when
added to exposure-outcome models acted as confounders
(changing beta estimates by ≥ 10%) and were statistically
significant (p < 0.05). Age and study site met these criteria
for all relationships. LM-BMD models were adjusted for
FMI and FM-BMD models were adjusted for ALMI. To
enable comparability to the literature we also adjusted for
menopausal status, cancer treatment, tamoxifen use, post-
menopausal hormone therapy use, and race/ethnicity. In-
clusion of these covariates in the models did not result in
substantial changes to the beta values obtained in age-
adjusted models. To further assure comparability with the
extant literature focusing on skeletal health among post-
menopausal women, we repeated analyses restricted to
postmenopausal women.
All analyses were performed in SAS version 9.2 (Cary,
NC). All tests were two-sided and statistical significance
was set at p < 0.05.
Results
At 6-months postdiagnosis, the mean age of participants
was 57 (±11) years, and the majority of women were
postmenopausal, non-Hispanic White, and not currently
using postmenopausal hormone therapy (Table 1). At
this time, about half of the women were taking tamoxi-
fen, and none were using aromatase inhibitors.
As shown in Table 2, higher vs. lower (Q4 vs. Q1) LM
was associated with higher BMD (1.12 g/cm2 vs. 1.07
g/cm2, p-trend < 0.0001) and higher vs. lower (Q4 vs. Q1)
FM was associated with higher BMD (1.12 g/cm2 vs.
1.07 g/cm2, p-trend < 0.0001).
As shown in Table 3, in stratified analyses by body fat-
ness and sarcopenia, higher vs. lower LM was associated
with BMD both in survivors with lower body fat (1.13
g/cm2 vs. 1.07 g/c, p-trend < 0.0001) and higher body fat(1.15 g/cm2 vs. 1.08 g/cm2, p-trend = 0.004). Higher vs.
lower FM was associated with BMD among non-sarcopenic
women (1.15 g/cm2 vs. 1.08 g/cm2, p < 0.0001); however,
among women with sarcopenia, the FM-BMD relationship
was in a similar direction and of comparable magnitude but
was not statistically significant (1.09 g/cm2 vs. 1.04 g/cm2,
p-trend = 0.18). When we repeated analyses among post-
menopausal women, results were similar (data not shown).
Table 2 Multivariate adjusted geometric means and 95%
confidence intervals of bone mineral density (BMD) by
quartiles of lean mass and fat mass
Quartile (Q) N Geometric mean
(95% CI) of BMD (g/cm2)
Lean Mass (kg)1
Q1 (26–36) 149 1.07 (1.04, 1.10)
Q2 (36–39) 150 1.09 (1.06, 1.13)
Q3 (39–43) 150 1.10 (1.07, 1.13)
Q4 (43–70) 150 1.12 (1.08, 1.15)
p-trend < 0.0001
Fat Mass (kg)2
Q1 (3–19) 149 1.07 (1.04, 1.10)
Q2 (19–25) 150 1.09 (1.06, 1.12)
Q3 (25–32) 150 1.09 (1.06, 1.12)
Q4 (32–68) 150 1.12 (1.09, 1.16)
< 0.0001
1Adjusted for age, menopausal status, postmenopausal hormone therapy use,
treatment at diagnosis, tamoxifen use, race/ethnicity, study site, and fat
mass index.
2Adjusted for age, menopausal status, postmenopausal hormone therapy use,
treatment at diagnosis, tamoxifen use, race/ethnicity, study site, and
appendicular lean mass index.
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in BMD among those who were not obese (10%) than
among those who were obese (3%), and FM explained
more variance in BMD among those who were not sarco-
penic (3%) than among those who were sarcopenic
(0.005%) (data not shown). In this study with its wide ageTable 3 Multivariate adjusted geometric means and 95% con
quartiles of lean mass and fat mass by body fatness and sarc
Women with fat mass index < = 12.9 kg/m2 (n = 4
Quartile (Q) N Geometric mean (95%
of BMD (g/cm2)
Lean Mass (kg)
Q1 (26–35) 118 1.07 (1.04, 1.11)
Q2 (35–38) 119 1.09 (1.06, 1.13)
Q3 (38–41) 119 1.10 (1.06, 1.13)
Q4 (41–57) 118 1.13 (1.09, 1.17)
p-trend < 0.0001
Women without sarcopenia (n = 515)2
Fat Mass (kg)
Q1 (3–20) 128 1.08 (1.05, 1.12)
Q2 (20–26) 129 1.11 (1.07, 1.14)
Q3 (26–33) 129 1.11 (1.07, 1.14)
Q4 (33–68) 129 1.15 (1.11, 1.19)
p-trend < 0.0001
1Adjusted for age, menopausal status, postmenopausal hormone therapy use, treat
2Sarcopenia status determined by appendicular lean mass index; without sarcopenirange, age explained more variance (8-18%) in BMD in all
univariate models than other variables (data not shown).
Discussion
Our results demonstrate the independent association of
LM and total body BMD among breast cancer survivors,
after controlling for relevant confounders, and confirmed
the role of FM in relation to total body BMD. This finding
showing the importance LM in relation to BMD is bio-
logically plausible, because dynamic rather than static loads
promote bone formation and retention [39,40], and adi-
pose tissue (FM) predominantly applies a static load on the
bone; in contrast, muscle tissue (LM) exerts a dynamic
strain on bone [15].
Rates of true bone loss among postmenopausal women
are reported to be approximately 3% per year [41]. The
cross-sectional differences in total body BMD observed
in our study for those in the highest vs. lowest quartiles of
LM (5%) and FM (5%) suggest clinical relevance. However,
since this is the first investigation on this topic among
breast cancer survivors, these observations require valid-
ation. Among survivors, some physical activity interven-
tions have promise in affecting both LM and BMD. Among
cancer survivors, postdiagnosis weight-bearing physical ac-
tivity and resistance training have been shown to increase
LM [29], and among postmenopausal breast cancer survi-
vors at risk for bone loss, postdiagnosis strength/weight
training has been shown to prevent loss of BMD [27,42].
More comprehensive and longitudinal research is needed
to understand how and the extent to which different types
and doses of physical activity affect both LM and BMD.fidence intervals of bone mineral density (BMD) by
openia status
74) Women with fat mass index > 12.9 kg/m2 (n = 125)
CI) Quartile (Q) N Geometric mean (95% CI)
of BMD (g/cm2)
Q1 (31–38) 31 1.08 (1.04, 1.12)
Q2 (38–43) 31 1.08 (1.04, 1.12)
Q3 (43–47) 32 1.13 (1.09, 1.17)
Q4 (47–70) 31 1.15 (1.11, 1.19)
p-trend 0.004
Women with sarcopenia (n = 84)2
Q1 (6–17) 21 1.04 (0.97, 1.12)
Q2 (17–20) 21 1.07 (0.97, 1.17)
Q3 (20–24) 21 1.08 (0.99, 1.18)
Q4 (24–34) 21 1.09 (0.99, 1.20)
p-trend 0.18
ment at diagnosis, tamoxifen use, race/ethnicity, study site.
a: ≥ 5.45 kg/m2, sarcopenic: < 5.45 kg/m2.
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breast cancer survivors ascertained through US population-
based cancer registries and the use of DXA to assess body
composition. This study also has some limitations. Al-
though this study also included a fairly diverse sample of
US Non-Hispanic White and Hispanic women, the gener-
alizability of our findings may be limited, and it will be im-
portant to extend this research to populations from other
cultures and race/ethnicities where some research suggests
that the association between body composition and BMD
may vary from that observed in white populations. In
addition, our cohort only included women with breast
cancer, so we are unable to compare associations observed
in survivors with those observed in women without can-
cer. Many of the body composition changes experienced
by breast cancer patients happen during and after treat-
ment, and the DXA measures collected in our study oc-
curred at one point in the time, approximately 6 months
post-diagnosis. Because our study only had a measure of
total body BMD, we were not able to examine associations
with spine or hip BMD, which would be most clinically
relevant. Our measure of total fat mass did not allow us to
break down the associations by types of adipose tissue,
such as visceral fat. Future studies with multiple, compre-
hensive measurements of body composition throughout
the cancer treatment process could identify critical pe-
riods of rapid bone loss.
We did not have data on recent bisphosphonate use,
osteoporosis, or comorbidities at the time of the 6-
months post-diagnosis assessment, so we were unable to
control for these factors. In addition, the cohort accrued
participants before the widespread use of aromatase inhib-
itors; therefore our study could not address associations
among women treated with these medications. Lastly, we
had very few patients with sarcopenia (n = 84), which lim-
ited our ability to draw conclusions about the association
of FM-BMD in this group, or the heterogeneity by sarco-
penia status.Conclusion
Within this large study of early-stage breast cancer survi-
vors, we found that higher LM was independently related
to higher total body BMD. Given breast cancer survivors’
increased risk for falls and fractures, replication of our re-
sults in other cohort studies could determine whether pre-
servation of LM results in meaningful reductions in bone
loss among breast cancer patients. Future exercise inter-
ventions to prevent bone loss among survivors should
consider the potential relevance of increasing and preserv-
ing LM.
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